Research programme: beta secretase inhibitors - Actelion

Drug Profile

Research programme: beta secretase inhibitors - Actelion

Alternative Names: Research programme: beta-secretase inhibitor

Latest Information Update: 27 Feb 2004

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Amyloid beta-protein precursor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 27 Feb 2004 This programme is still in active development - (JP Morgan 22nd Annual Healthcare Conference)
  • 03 Feb 2003 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top